What is the current valuation of the Drug of Abuse Testing Market?

The Drug of Abuse Testing Market was valued at 4.92 USD Billion in 2024. Read More

What is the projected market size for the Drug of Abuse Testing Market by 2035?

The market is projected to reach 8.197 USD Billion by 2035. Read More

What is the expected CAGR for the Drug of Abuse Testing Market during the forecast period 2025 - 2035?

The expected CAGR for the market during 2025 - 2035 is 4.75%. Read More

Which companies are considered key players in the Drug of Abuse Testing Market?

Key players include Abbott Laboratories, Thermo Fisher Scientific, Quest Diagnostics, and Roche Diagnostics. Read More

What are the primary testing methods used in the Drug of Abuse Testing Market?

The primary testing methods include immunoassays, chromatography, and spectrometry. Read More

How does urine testing compare to blood testing in terms of market valuation?

Urine testing was valued at 1.96 USD Billion in 2024 and is projected to grow to 3.25 USD Billion by 2035, while blood testing was valued at 1.25 USD Billion and is expected to reach 2.0 USD Billion. Read More

What is the market valuation for saliva testing and hair testing in 2024?

Saliva testing was valued at 0.75 USD Billion and hair testing at 0.96 USD Billion in 2024. Read More

Which end-use segment is expected to see the highest growth in the Drug of Abuse Testing Market?

The hospitals segment, valued at 1.476 USD Billion in 2024, is projected to grow to 2.5 USD Billion by 2035. Read More

What substances are primarily tested in the Drug of Abuse Testing Market?

The primary substances tested include cannabis, cocaine, opiates, and amphetamines. Read More

What is the projected market valuation for cannabis testing by 2035?

Cannabis testing is projected to grow from 1.5 USD Billion in 2024 to 2.5 USD Billion by 2035. Read More

Drug Abuse Testing Market

Drug of Abuse Testing Market Research Report By Test Type (Urine Testing, Blood Testing, Saliva Testing, Hair Testing), By Methodology (Immunoassays, Chromatography, Spectrometry), By End Use (Hospitals, Laboratories, Workplaces, Home Care), By Substance Tested (Cannabis, Cocaine, Opiates, Amphetamines, Phencyclidine) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

4.75%

2024 Market Size

$ 4.92 Billion

2035 Market Size

$ 8.2 Billion

Pharmaceutical ● Updated August 24, 2026 Report ID: MRFR/Pharma/1398-CR | Pages: 92 | Author: Nidhi Mandole, Rahul Gotadki

Summary Table of Contents Segmentation Methodology Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Test Type (USD Billion) | |
  1. 4.1.1 Urine Testing | |
  2. 4.1.2 Blood Testing | |
  3. 4.1.3 Saliva Testing | |
  4. 4.1.4 Hair Testing |
2. 4.2 Healthcare, BY Methodology (USD Billion) | |
  1. 4.2.1 Immunoassays | |
  2. 4.2.2 Chromatography | |
  3. 4.2.3 Spectrometry |
3. 4.3 Healthcare, BY End Use (USD Billion) | |
  1. 4.3.1 Hospitals | |
  2. 4.3.2 Laboratories | |
  3. 4.3.3 Workplaces | |
  4. 4.3.4 Home Care |
4. 4.4 Healthcare, BY Substance Tested (USD Billion) | |
  1. 4.4.1 Cannabis | |
  2. 4.4.2 Cocaine | |
  3. 4.4.3 Opiates | |
  4. 4.4.4 Amphetamines | |
  5. 4.4.5 Phencyclidine |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Abbott Laboratories (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Thermo Fisher Scientific (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Quest Diagnostics (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Alere Inc. (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Roche Diagnostics (CH) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Siemens Healthineers (DE) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Labcorp (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Medtox Scientific (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Psychemedics Corporation (US) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TEST TYPE |
7. 6.4 US MARKET ANALYSIS BY METHODOLOGY |
8. 6.5 US MARKET ANALYSIS BY END USE |
9. 6.6 US MARKET ANALYSIS BY SUBSTANCE TESTED |
10. 6.7 CANADA MARKET ANALYSIS BY TEST TYPE |
11. 6.8 CANADA MARKET ANALYSIS BY METHODOLOGY |
12. 6.9 CANADA MARKET ANALYSIS BY END USE |
13. 6.10 CANADA MARKET ANALYSIS BY SUBSTANCE TESTED |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TEST TYPE |
16. 6.13 GERMANY MARKET ANALYSIS BY METHODOLOGY |
17. 6.14 GERMANY MARKET ANALYSIS BY END USE |
18. 6.15 GERMANY MARKET ANALYSIS BY SUBSTANCE TESTED |
19. 6.16 UK MARKET ANALYSIS BY TEST TYPE |
20. 6.17 UK MARKET ANALYSIS BY METHODOLOGY |
21. 6.18 UK MARKET ANALYSIS BY END USE |
22. 6.19 UK MARKET ANALYSIS BY SUBSTANCE TESTED |
23. 6.20 FRANCE MARKET ANALYSIS BY TEST TYPE |
24. 6.21 FRANCE MARKET ANALYSIS BY METHODOLOGY |
25. 6.22 FRANCE MARKET ANALYSIS BY END USE |
26. 6.23 FRANCE MARKET ANALYSIS BY SUBSTANCE TESTED |
27. 6.24 RUSSIA MARKET ANALYSIS BY TEST TYPE |
28. 6.25 RUSSIA MARKET ANALYSIS BY METHODOLOGY |
29. 6.26 RUSSIA MARKET ANALYSIS BY END USE |
30. 6.27 RUSSIA MARKET ANALYSIS BY SUBSTANCE TESTED |
31. 6.28 ITALY MARKET ANALYSIS BY TEST TYPE |
32. 6.29 ITALY MARKET ANALYSIS BY METHODOLOGY |
33. 6.30 ITALY MARKET ANALYSIS BY END USE |
34. 6.31 ITALY MARKET ANALYSIS BY SUBSTANCE TESTED |
35. 6.32 SPAIN MARKET ANALYSIS BY TEST TYPE |
36. 6.33 SPAIN MARKET ANALYSIS BY METHODOLOGY |
37. 6.34 SPAIN MARKET ANALYSIS BY END USE |
38. 6.35 SPAIN MARKET ANALYSIS BY SUBSTANCE TESTED |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TEST TYPE |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY METHODOLOGY |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY SUBSTANCE TESTED |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TEST TYPE |
45. 6.42 CHINA MARKET ANALYSIS BY METHODOLOGY |
46. 6.43 CHINA MARKET ANALYSIS BY END USE |
47. 6.44 CHINA MARKET ANALYSIS BY SUBSTANCE TESTED |
48. 6.45 INDIA MARKET ANALYSIS BY TEST TYPE |
49. 6.46 INDIA MARKET ANALYSIS BY METHODOLOGY |
50. 6.47 INDIA MARKET ANALYSIS BY END USE |
51. 6.48 INDIA MARKET ANALYSIS BY SUBSTANCE TESTED |
52. 6.49 JAPAN MARKET ANALYSIS BY TEST TYPE |
53. 6.50 JAPAN MARKET ANALYSIS BY METHODOLOGY |
54. 6.51 JAPAN MARKET ANALYSIS BY END USE |
55. 6.52 JAPAN MARKET ANALYSIS BY SUBSTANCE TESTED |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TEST TYPE |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY METHODOLOGY |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY SUBSTANCE TESTED |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TEST TYPE |
61. 6.58 MALAYSIA MARKET ANALYSIS BY METHODOLOGY |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END USE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY SUBSTANCE TESTED |
64. 6.61 THAILAND MARKET ANALYSIS BY TEST TYPE |
65. 6.62 THAILAND MARKET ANALYSIS BY METHODOLOGY |
66. 6.63 THAILAND MARKET ANALYSIS BY END USE |
67. 6.64 THAILAND MARKET ANALYSIS BY SUBSTANCE TESTED |
68. 6.65 INDONESIA MARKET ANALYSIS BY TEST TYPE |
69. 6.66 INDONESIA MARKET ANALYSIS BY METHODOLOGY |
70. 6.67 INDONESIA MARKET ANALYSIS BY END USE |
71. 6.68 INDONESIA MARKET ANALYSIS BY SUBSTANCE TESTED |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TEST TYPE |
73. 6.70 REST OF APAC MARKET ANALYSIS BY METHODOLOGY |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END USE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY SUBSTANCE TESTED |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TEST TYPE |
78. 6.75 BRAZIL MARKET ANALYSIS BY METHODOLOGY |
79. 6.76 BRAZIL MARKET ANALYSIS BY END USE |
80. 6.77 BRAZIL MARKET ANALYSIS BY SUBSTANCE TESTED |
81. 6.78 MEXICO MARKET ANALYSIS BY TEST TYPE |
82. 6.79 MEXICO MARKET ANALYSIS BY METHODOLOGY |
83. 6.80 MEXICO MARKET ANALYSIS BY END USE |
84. 6.81 MEXICO MARKET ANALYSIS BY SUBSTANCE TESTED |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TEST TYPE |
86. 6.83 ARGENTINA MARKET ANALYSIS BY METHODOLOGY |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END USE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY SUBSTANCE TESTED |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TEST TYPE |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY METHODOLOGY |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY SUBSTANCE TESTED |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TEST TYPE |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY METHODOLOGY |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY SUBSTANCE TESTED |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TEST TYPE |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY METHODOLOGY |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY SUBSTANCE TESTED |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TEST TYPE |
103. 6.100 REST OF MEA MARKET ANALYSIS BY METHODOLOGY |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END USE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY SUBSTANCE TESTED |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TEST TYPE, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TEST TYPE, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY METHODOLOGY, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY METHODOLOGY, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END USE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END USE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY SUBSTANCE TESTED, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY SUBSTANCE TESTED, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TEST TYPE, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY METHODOLOGY, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END USE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY SUBSTANCE TESTED, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Drug Abuse Testing Market Segmentation

Drug Abuse Testing Market By Test Type (USD Billion, 2025-2035)

Urine Testing
Blood Testing
Saliva Testing
Hair Testing

Drug Abuse Testing Market By Methodology (USD Billion, 2025-2035)

Immunoassays
Chromatography
Spectrometry

Drug Abuse Testing Market By End Use (USD Billion, 2025-2035)

Hospitals
Laboratories
Workplaces
Home Care

Drug Abuse Testing Market By Substance Tested (USD Billion, 2025-2035)

Cannabis
Cocaine
Opiates
Amphetamines
Phencyclidine

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”